News

Inflammatix Raises $57M in Series E Financing NEW YORK, Sep 12, 2024 — Molecular diagnostics firm Inflammatix said Thursday that it has raised $57 million in a Series E funding round. The round was led by Khosla Ventures and Think.Health with participation from Northpond Ventures, D1 Capital Partners, Iberis Capital, Vesalius BioCapital, OSF Healthcare, and RAW Ventures, among others. The

HepaRegeniX raises €15 million Series C round to advance clinical development of HRX-215 for liver Regeneration Funds to support Phase Ib clinical trial of HRX-215 in the US and an international multicenter Phase IIa clinical trial in liver regeneration Elias Papatheodorou moves from Chair of the Board to CEO of HepaRegeniX Dr. Linda Greenbaum joins HepaRegeniX as CMO Tuebingen (Germany),

Inheart raises $11M to accelerate development & deployment of novel therapeuthic, predictive, and screening cardiac solutions Funding supports commercial expansion of inHEART’s digital twin of the heart in the US, EU, Asia Pacific, and Middle East markets, as well as the development of new software solutions across the cardiac care continuum May 6, 2024 — Cambridge, MA, and Bordeaux, France

Cognivia Secures Strategic 15.5M€ Funding to Empower Drug Development with AI-ML Solutions Using patient personality traits to pioneer a new era in clinical research. MONT-SAINT-GUIBERT, Belgium, April 18, 2024 – Cognivia, an innovative AI company dedicated to reshaping pharmaceutical and biotech clinical research through cutting edge AI-ML algorithms, proudly announces a significant investment milestone. Vesalius Biocapital IV, SFPIM (Société Fédérale

Vesalius Biocapital Announces First Close of Fourth Fund Raising EUR 95 Million Significant support from investors including the European Investment Fund Fund to invest in first and best-in-class European life science companies in drug development and digital health Luxembourg-Strassen, 29 June 2023 – Vesalius Biocapital, the specialist life sciences venture capital investor, announces the first close of its fourth fund,